Navigation Links
Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results
Date:12/3/2009

TUSTIN, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7:00 a.m. EST and will host a conference call and webcast to discuss the results at 11:30 a.m. EST on the same day.

Peregrine's senior management will discuss financial results for the second quarter ended October 31, 2009 and will review recent operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the archived webcast.

The conference call and webcast will begin at 11:30 a.m. EST/ 8:30 a.m. PST. To listen to a live broadcast of the call over the Internet or to review the archived webcast, please visit: www.peregrineinc.com. The webcast will be archived on Peregrine's website for 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through December 17, 2009 by calling (877) 344-7529, passcode 431883#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and serious virus infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara®. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.


Contacts:
GendeLLindheim BioCom Partners
Investors                                 Media
---------                                 -----
info@peregrineinc.com                     Barbara Lindheim
(800) 987-8256                            (212) 918-4650

SOURCE Peregrine Pharmaceuticals, Inc.


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial
2. Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
3. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
4. Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
5. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
6. Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
7. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
8. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
9. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
10. Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
11. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Aratana Therapeutics, Inc. (NASDAQ: PETX ... development and commercialization of innovative biopharmaceutical products for companion ... North America 2016. ... on the FDA approval of three innovative therapeutics in ... (capromorelin oral solution) and NOCITA ® (bupivacaine liposome ...
(Date:1/20/2017)... BOSTON , Jan. 20, 2017 ... acquisition of Gen9, a pioneer in the synthesis ... Gen9,s unique expertise in assembling pathway-length synthetic DNA ... speed and capacity in the construction of new ... of industries. "Gen9 was founded to ...
(Date:1/19/2017)... , Jan. 19, 2017  Market Research Future has a half ... for Liquid Biopsy is growing rapidly and expected to reach USD ... Market Highlights ... Global Liquid Biopsy Market has been assessed as a swiftly growing ... and boom in the coming future. There has been a tremendous ...
(Date:1/19/2017)... , ... January 19, 2017 ... ... advanced software solutions for pharmaceutical research and development (R&D), today announced the ... omic data analysis and interpretation for the rapidly evolving field of precision ...
Breaking Biology Technology:
(Date:1/4/2017)...  For the thousands of attendees at this year,s International Consumer Electronics ... and biometric measurement devices and services, will be featuring its new line ... A&D Medical,s special CES Exhibit Suite , the new upper arm ... company,s WellnessConnected product platform.  ... ...
(Date:1/3/2017)... Jan. 3, 2017 Onitor, provider of digital ... Onitor Track, an innovative biometric data-driven program designed to ... month at the 2017 Consumer Electronics Show (CES) in ... In the U.S., the World Health Organization (WHO), have ... of adults who are overweight or obese. WHO also ...
(Date:12/22/2016)... , December 22, 2016 SuperCom (NASDAQ: ... secure solutions for the e-Government, Public Safety, HealthCare, and Finance sectors ... SuperCom, has been selected to implement and deploy a community-based supportive ... Northern California , further expanding its presence in the ... This new ...
Breaking Biology News(10 mins):